截至6月30日，博拓生物股东户数5583.00，较上期减少10.13%；人均流通股26747股，较上期增加 55.77%。2025年1月-6月，博拓生物实现营业收入2.03亿元，同比减少23.91%；归母净利润1240.24万 元，同比减少82.82%。 分红方面，博拓生物A股上市后累计派现7.98亿元。近三年，累计派现4.78亿元。 机构持仓方面，截止2025年6月30日，博拓生物十大流通股东中，广发价值核心混合A（010377）位居 第六大流通股东，持股423.60万股，相比上期增加150.21万股。 9月15日，博拓生物跌0.12%，成交额9922.65万元。两融数据显示，当日博拓生物获融资买入额1943.01 万元，融资偿还1484.11万元，融资净买入458.89万元。截至9月15日，博拓生物融资融券余额合计2.00 亿元。 融资方面，博拓生物当日融资买入1943.01万元。当前融资余额2.00亿元，占流通市值的3.15%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，博拓生物9月15日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融 ...

Group 1 - The core point of the news is that 博拓生物's stock price has decreased by 5.01%, currently trading at 39.05 CNY per share, with a total market capitalization of 58.31 billion CNY [1] - 博拓生物, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 92.91% of its revenue coming from diagnostic reagent products [1] - The trading volume for 博拓生物 reached 2.27 billion CNY, with a turnover rate of 3.76% [1] Group 2 - From the perspective of major shareholders, 广发价值核心混合A (010377) holds 2.56% of 博拓生物's circulating shares, with a current floating loss of approximately 563.17 million CNY [2] - The fund has achieved a return of 68.54% year-to-date and 114.67% over the past year, ranking 147 out of 8194 and 129 out of 7963 respectively [2] - The fund manager, 吴远怡, has been in charge for 4 years and 333 days, with a total asset scale of 204.78 billion CNY [3] Group 3 - In the second quarter, 广发价值核心混合A (010377) held 423.6 million shares of 博拓生物, representing 2.75% of the fund's net value, making it the eighth largest holding [4] - The current floating loss for the fund regarding 博拓生物 is estimated at 872.62 million CNY [4]

Group 1 - On August 25, Botao Bio's stock increased by 0.15% with a trading volume of 201 million yuan [1] - The financing data shows that on the same day, Botao Bio had a financing purchase amount of 23.34 million yuan and a financing repayment of 26.15 million yuan, resulting in a net financing buy of -2.81 million yuan [1] - As of August 25, the total balance of margin trading for Botao Bio was 190 million yuan, which accounts for 3.11% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of March 31, the number of shareholders for Botao Bio was 6,212, a decrease of 2.11% from the previous period [2] - For the first quarter of 2025, Botao Bio reported an operating income of 87.89 million yuan, a year-on-year decrease of 35.20%, and a net profit attributable to shareholders of 8.73 million yuan, down 77.97% year-on-year [2] - Since its A-share listing, Botao Bio has distributed a total of 798 million yuan in dividends, with 478 million yuan distributed over the past three years [2]